Mouth Care Regimes During Radiotherapy
|ClinicalTrials.gov Identifier: NCT00138827|
Recruitment Status : Completed
First Posted : August 30, 2005
Last Update Posted : December 15, 2005
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Neoplasms||Drug: Biotene (mouth care)||Phase 4|
Grade III and IV mucositis occurs in 30-60% of patients undergoing head and neck irradiation. Where mucositis is severe a patient’s ability to swallow may become significantly compromised and nutritional requirements may not be met.
Xerostomia is often an early side effect of treatment. As salivary tissue is very sensitive to radiation there is often a change in saliva early in the treatment.
New products on the market have claimed to alleviate the symptoms of dry mouth and to help the body’s natural defenses reduce the harmful oral bacteria. These products contain the important salivary enzymes lactoperoxidase, lysozyme, lactoferrin and glucose oxidase. Biotene products therefore have the potential to reduce microbial populations which result in radiation caries and periodontal disease and in addition provide relief from the discomfort of xerostomia.
Despite the knowledge surrounding xerostomia in the head and neck irradiation population, its treatment has not been well documented and the question of patient comfort is not well addressed.
Comparisons: This study aims to compare the different mouth care regimes and determine the most effective treatment alternatives during radiotherapy. Patients will be randomised to either Biotene or Bicarbonate-based mouth care regimes. Patients will be stratified according to whether they are receiving radiotherapy alone or chemo irradiation to ensure equal distribution across the different mouth care regimes.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy|
|Study Start Date :||November 1999|
|Study Completion Date :||March 2003|
- Mid treatment, 2 and 6 weeks post treatment relative to baseline: Oral comfort – dichotomised as difficulty yes/no based on 3 questions
- Mucositis – dichotomised
- Xerostomia – dichotomised
- Pain medications – dichotomised
- Oral flora
- Oral pH
- Salivary flow
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00138827
|Australia, New South Wales|
|St George Hospital, Cancer Care Centre|
|Sydney, New South Wales, Australia, 2217|
|Principal Investigator:||Associate Professor Peter H Graham||St George Hospital, Sydney, Australia|